Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

被引:5
|
作者
Holz, Frank G. [1 ]
Tadayoni, Ramin [3 ]
Beatty, Stephen [4 ]
Berger, Alan R. [5 ,6 ]
Cereda, Matteo G. [7 ]
Hykin, Philip [8 ]
Hoyng, Carel B. [10 ]
Wittrup-Jensen, Kim [2 ]
Altemark, Andreas [2 ]
Nilsson, Jonas [11 ]
Kim, Kun [12 ]
Sivaprasad, Sobha [8 ,9 ]
机构
[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[2] Bayer Pharmaceut, Berlin, Germany
[3] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France
[4] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland
[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[6] St Michaels Hosp, Toronto, ON, Canada
[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[8] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England
[9] Kings Coll Hosp London, Dept Ophthalmol, London, England
[10] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands
[11] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden
[12] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden
关键词
AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD;
D O I
10.1159/000449001
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [41] Epiretinal Membranes in Neovascular Age-Related Macular Degeneration: Effect on Outcomes of Anti-VEGF Therapy
    Karaca, Emine Esra
    Yildiz, Burcin Kepez
    Ozdek, Sengul
    OPHTHALMOLOGICA, 2014, 232 : 5 - 6
  • [42] Visual and Anatomic Responses in Patients With Neovascular Age-Related Macular Degeneration and a Suboptimal Response to Anti-VEGF Therapy Switched to Faricimab
    Khodor, Ali
    Choi, Stephanie
    Nanda, Tavish
    Caranfa, Jonathan T.
    Ruiz-Lozano, Raul E.
    Desai, Shilpa H.
    Liang, Michelle
    Baumal, Caroline R.
    Reed, David C.
    Cleary, Tina S.
    Heier, Jeffrey S.
    Shah, Chirag P.
    Witkin, Andre J.
    JOURNAL OF VITREORETINAL DISEASES, 2024, 8 (06) : 643 - 650
  • [43] Influence of seasonal sunlight intensity and iris color on the anti-VEGF therapy for neovascular age-related macular degeneration
    Brockmann, C.
    Brockmann, T.
    Dawczynski, J.
    EYE, 2013, 27 (10) : 1169 - 1173
  • [44] Ganglion Cell Layer Thickness Change in Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Injections
    Mantopoulos, Dimosthenis
    Ray, Hetal
    Sanchez, George
    Pokroy, Russell
    Roth, Daniel B.
    JOURNAL OF VITREORETINAL DISEASES, 2022, 6 (02) : 126 - 131
  • [45] Changes in Neovascular Lesion Hyperreflectivity After Anti-VEGF Treatment in Age-Related Macular Degeneration: An Integrated Multimodal Imaging Analysis
    Casalino, Giuseppe
    Bandello, Francesco
    Chakravarthy, Usha
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (09) : OCT288 - OCT298
  • [46] Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
    Hussain, Rehan M.
    Neal, Andrea
    Yannuzzi, Nicolas A.
    Patel, Kevin H.
    Huo, Siya
    Hariprasad, Seenu M.
    Bhatia, Sumit P.
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2021, 13
  • [47] Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration
    Jaffe, Glenn J.
    Ciulla, Thomas A.
    Ciardella, Antonio P.
    Devin, Francois
    Dugel, Pravin U.
    Eandi, Chiara M.
    Masonson, Harvey
    Mones, Jordi
    Pearlman, Joel A.
    Quaranta-El Maftouhi, Maddalena
    Ricci, Federico
    Westby, Keith
    Patel, Samir C.
    OPHTHALMOLOGY, 2017, 124 (02) : 224 - 234
  • [48] OCT-Derived Radiomic Features Predict Anti-VEGF Response and Durability in Neovascular Age-Related Macular Degeneration
    Kar, Sudeshna Sil
    Cetin, Hasan
    Lunasco, Leina
    Le, Thuy K.
    Zahid, Robert
    Meng, Xiangyi
    Srivastava, Sunil K.
    Madabhushi, Anant
    Ehlers, Justis P.
    OPHTHALMOLOGY SCIENCE, 2022, 2 (04):
  • [49] Efficacy of Intravitreal Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration Patients with or without Polypoidal Choroidal Vasculopathy: A Meta-Analysis
    Wang, Luyao
    Liu, Shiyu
    He, Tingting
    Liu, Chun
    Duan, Junguo
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
  • [50] CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration
    Yildiz, Burcin Kepez
    Ozdek, Sengul
    Ergun, Mehmet Ali
    Ergun, Sezen
    Tuncay, Fulya Yaylacioglu
    Elbeg, Sehri
    OPHTHALMIC RESEARCH, 2016, 56 (03) : 132 - 138